Earlier analysis of data from KEYNOTE clinical trials showed that tumour mutational burden (TMB) and an 18-gene T-cell inflamed, IFNγ-related gene expression profile (GEP) has predictive value in identifying anti-PD-1 responders and non-responders7,18. The gene discussed is IFNG; the disease is neoplasm.